RxDoctor Payments Data

Arturo Otero, MD

Neurology · Tuscaloosa, ALNPI 1437253044

Payments from drug & device makers

$14,827in general payments, 2019–2025

Across 849 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$1K
  • Biogen$1K
  • Pfizer$1K
  • CSL Behring$995
  • Amgen$659
  • plus $7K from 54 others

What the payments were for

  • Speaking & faculty fees$290%
  • Food & beverage$14,74999%
  • Education$490%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)153$2,252
Novartis74$1,274
Biogen68$1,062
Pfizer79$1,035
CSL Behring29$995
Amgen(2 entities)34$659
UCB, Inc.30$617
Neurocrine Biosciences, Inc.20$383
Teva Pharmaceuticals USA, Inc.42$381
Argenx US, Inc.14$323
Lilly USA, LLC21$317
Neurelis, Inc.20$296
Eisai Inc.11$293
Upsher-smith Laboratories LLC14$285
Genentech USA, Inc.14$278
SK Life Science, Inc.10$235
AstraZeneca10$213
Johnson & Johnson(2 entities)11$200
EMD Serono, Inc.9$195
Sunovion Pharmaceuticals Inc.11$186
Lundbeck LLC8$181
Otsuka America Pharmaceutical, Inc.8$169
Biohaven Pharmaceutical Holding Company Ltd.6$159
Takeda Pharmaceuticals U.S.A., Inc.7$156
Supernus Pharmaceuticals, Inc.7$156
Bristol Myers Squibb9$153
Merz Pharmaceuticals, LLC6$130
MDD US Operations, LLC7$119
Sanofi6$118
Catalyst Pharmaceuticals, Inc.5$109
Acorda Therapeutics, Inc6$105
Strongbridge US Inc.8$105
Akcea Therapeutics, Inc.6$98
Greenwich Biosciences, Inc.6$97
Ipsen Biopharmaceuticals, Inc5$96
Scilex Pharmaceuticals Inc.5$96
Acadia Pharmaceuticals Inc6$93
Biohaven Pharmaceuticals, Inc.4$84
Tanabe Pharma America, Inc.4$82
Amneal Pharmaceuticals LLC4$67
Jazz Pharmaceuticals Inc.3$65
Avanir Pharmaceuticals, Inc.3$58
ANI Pharmaceuticals, Inc.2$51
Grifols USA, LLC3$49
Alnylam Pharmaceuticals Inc.2$45
Averitas Pharma Inc.2$45
GE HealthCare2$42
Harmony Biosciences LLC2$42
Aucta Pharmaceuticals, Inc.2$42
TG Therapeutics, Inc.2$40
Assertio Therapeutics, Inc.3$38
Impel Pharmaceuticals Inc.2$38
Aquestive Therapeutics, Inc.3$37
Mallinckrodt Hospital Products Inc.1$34
Zyla Life Sciences, Inc.2$34
Kyowa Kirin, Inc.2$33
Adamas Pharmaceuticals, Inc.2$30
E.r. Squibb & Sons, L.L.C.2$30
Livanova USA, Inc.1$26
Banner Life Sciences, LLC1$25

How this compares

$14,827 in reported general payments places this provider in the 65th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$254,299
Medicare patients
418
Services billed
8,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcrevusOcrelizumab12$464,694
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$344,583
VumerityDiroximel Fumarate23$208,247
Avonex (4 Pack)Interferon Beta-1a13$107,514
AustedoDeutetrabenazine12$87,857
QuliptaAtogepant71$86,227
NuplazidPimavanserin Tartrate16$67,908
KeppraLevetiracetam26$59,296
BriviactBrivaracetam32$58,658
Nurtec OdtRimegepant Sulfate36$54,764
Gamunex-CImmune Globul G/Gly/Iga Avg 4626$45,024
Topiramate ErTopiramate21$30,454
Oxtellar XrOxcarbazepine14$26,586
Sumatriptan Succinate81$25,580
BotoxOnabotulinumtoxina20$23,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$156$344,58313 claims
BiogenVumerity, Avonex (4 Pack)$1,062$315,76136 claims
AbbVieQulipta, Botox$2,252$109,46491 claims
Teva Pharmaceuticals USA, Inc.Austedo$381$87,85712 claims
UCB, Inc.Briviact, Neupro$617$70,77445 claims
Acadia Pharmaceuticals IncNuplazid$93$67,90816 claims
PfizerNurtec Odt$1,035$54,76436 claims
Grifols USA, LLCGamunex-C$49$45,02426 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$156$26,58614 claims
Eisai Inc.Fycompa$293$10,77515 claims
Upsher-smith Laboratories LLCTopiramate$285$2,746223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 255 neurology providers in Alabama.

Other neurology in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →